Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
03 Septembre 2024 - 1:00PM
Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission
it is to develop medicines that meaningfully improve and extend the
lives of patients facing deadly diseases, today announced that Mike
Andriole, Chief Executive Officer, will present a corporate
presentation at the H.C. Wainwright 26th Annual Global Investment
Conference made available on Monday, September 9, 2024 at 7:00 a.m.
ET.
An audio webcast of the presentation will be available on the
Investor Relations section of Chimerix's website at
ir.chimerix.com, where it will be archived for approximately 90
days.
About Chimerix Chimerix is a biopharmaceutical
company with a mission to develop medicines that meaningfully
improve and extend the lives of patients facing deadly diseases.
The Company’s most advanced clinical-stage development program,
ONC201, is in development for H3 K27M-mutant glioma.
The Company is conducting Phase 1 dose escalation studies of ONC206
to evaluate safety and PK data.
CONTACT:
Will O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Chimerix (NASDAQ:CMRX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
